Literature DB >> 2675676

Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.

M G Larach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2675676

Source DB:  PubMed          Journal:  Anesth Analg        ISSN： 0003-2999            Impact factor:   5.108


× No keyword cloud information.
  50 in total

1.  Kinetics of dissolution of gaseous halothane in Krebs-Ringer's solution.

Authors:  M S Millman; M Young
Journal:  Can J Anaesth       Date:  1992-11       Impact factor: 5.063

2.  Malignant hyperthermia susceptibility diagnosed with a family-specific ryanodine receptor gene type 1 mutation.

Authors:  Takahiro Tanabe; Makoto Fukusaki; Yoshiaki Terao; Kazunori Yamashita; Koji Sumikawa; Keiko Mukaida; Carlos A Ibarra; Ichizo Nishino
Journal:  J Anesth       Date:  2008-02-27       Impact factor: 2.078

3.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

4.  Evidence for genetic heterogeneity of malignant hyperthermia susceptibility.

Authors:  T Deufel; A Golla; D Iles; A Meindl; T Meitinger; D Schindelhauer; A DeVries; D Pongratz; D H MacLennan; K J Johnson
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

5.  Clinical utility gene card for: malignant hyperthermia.

Authors:  Henry Rosenberg; Henrik Rueffert
Journal:  Eur J Hum Genet       Date:  2011-01-19       Impact factor: 4.246

Review 6.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

7.  A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.

Authors:  Carlos A Ibarra Moreno; Natalia Kraeva; Elena Zvaritch; Lourdes Figueroa; Eduardo Rios; Leslie Biesecker; Filip Van Petegem; Philip M Hopkins; Sheila Riazi
Journal:  Br J Anaesth       Date:  2020-08-27       Impact factor: 9.166

8.  Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree.

Authors:  J M Healy; K A Quane; K E Keating; M Lehane; J J Heffron; T V McCarthy
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

9.  Central core disease: clinical, pathological, and genetic features.

Authors:  R M Quinlivan; C R Muller; M Davis; N G Laing; G A Evans; J Dwyer; J Dove; A P Roberts; C A Sewry
Journal:  Arch Dis Child       Date:  2003-12       Impact factor: 3.791

10.  Abnormal human sarcoplasmic reticulum Ca2+ release channels in malignant hyperthermic skeletal muscle.

Authors:  M Fill; E Stefani; T E Nelson
Journal:  Biophys J       Date:  1991-05       Impact factor: 4.033
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.